- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07941310
A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal Cancer
A Phase 2, Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Erlotinib in Patients With EGFR-Amplified Metastatic Colorectal Cancer Who Have Failed or Are Not Eligible for Oxaliplatin- and Irinotecan-Based Chemotherapy
This phase II, open-label, single-arm clinical trial is designed to evaluate the efficacy and safety of a combination therapy with bevacizumab and erlotinib as a salvage treatment in patients with metastatic colorectal cancer who have failed or are intolerant to standard oxaliplatin- and irinotecan-based chemotherapy, and whose tumors harbor an EGFR copy number gain of 4 or higher confirmed by NGS testing. The primary objective is to evaluate progression-free survival (PFS), and secondary objectives include objective response rate (ORR), overall survival (OS), disease control rate (DCR), safety, and quality of life.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
This study investigates the clinical benefit of combining an anti-VEGF agent (bevacizumab) with an EGFR tyrosine kinase inhibitor (erlotinib) in refractory metastatic colorectal cancer with EGFR amplification. Eligible patients will receive bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral erlotinib at 150 mg. Tumor assessments will be conducted periodically using RECIST version 1.1 to determine clinical outcomes, and toxicities will be graded according to NCI CTCAE version 5.0.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Soohyeon Lee, MD, PhD
- Sähköposti: soohyeon_lee@korea.ac.kr
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Histologically or cytologically proven metastatic/recurrent colorectal cancer who have failed or are intolerant to standard chemotherapy based on oxaliplatin and irinotecan (and if RAS wild-type, an anti-EGFR therapy).
-
EGFR copy number gain ≥ 4 confirmed by NGS testing performed at the participating institution.
-
Measurable disease per RECIST version 1.1 (measurable lesions are not mandatory for study entry).
-
Age ≥ 19 years.
-
ECOG performance status 0-2.
-
Adequate bone marrow and organ function:
- Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L
- Hemoglobin (Hgb) ≥ 9.0 g/dL
- Platelet count ≥ 75 x 10^9/L
- Serum creatinine ≤ 1.5 x ULN or creatinine clearance > 30 mL/min
- Total bilirubin ≤ 2.0 x ULN (subjects with biliary obstruction are eligible if criteria are met after appropriate biliary drainage)
- AST and ALT ≤ 3 x ULN (or ≤ 5 x ULN if liver metastases are present)
-
Adequate cardiac function: QTc ≤ 480 msec (if QTc > 480 msec, average QTc < 480 msec in triplicate measurements).
-
Ability to swallow oral medication.
-
Negative serum β-HCG pregnancy test within 14 days prior to study drug administration for female patients of childbearing potential.
-
Agreement to use appropriate contraception methods as outlined in the protocol.
-
Life expectancy ≥ 3 months.
-
Signed and dated informed consent prior to any study-related procedures.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Prior history of combination therapy with an EGFR tyrosine kinase inhibitor and anti-VEGF blockade.
- Known hypersensitivity to the study drug components.
- Cytotoxic chemotherapy within 14 days, investigational drugs within 2 weeks or 5 half-lives, or monoclonal antibody therapy within 4 weeks prior to study entry.
- Uncontrolled severe infection.
- Severe medical or psychiatric conditions including active cardiac disease, uncontrolled hypertension, significant arrhythmias, or conditions prolonging QTc.
- Active central nervous system (CNS) metastases (unless radiologically stable, asymptomatic, and off steroids for at least 4 weeks; leptomeningeal disease is excluded).
- History of another primary malignancy (except adequately treated non-melanoma skin cancer, superficial cervical carcinoma, stage 1 bladder cancer, completely resected thyroid cancer, or other solid tumors with no evidence of recurrence for at least 36 months).
- Persistence of toxicities from prior anticancer therapy > Grade 1 (except alopecia).
- Extensive radiotherapy to the bone marrow within 4 weeks or limited radiotherapy within 2 weeks prior to study entry.
- Major surgery within 4 weeks prior to study entry or unrecovered from surgical side effects.
- Thrombotic or thromboembolic events within 6 months.
- History or evidence of bleeding disorders.
- Therapeutic use of maximum dose anticoagulants.
- Unhealed wounds, acute ulcers, or bone fractures.
- Abdominal fistula, gastrointestinal perforation, or active GI bleeding within 6 months.
- Urine dipstick protein ≥ 2+ with 24-hour urine protein > 1g.
- History or pathological findings of major GI surgery that may impair oral absorption.
- Evidence of active infection including Hepatitis B, Hepatitis C, or HIV (subjects with controlled or inactive HBV/HCV under specific protocol criteria are permitted).
- Conditions or diseases deemed by the investigator to contraindicate study participation.
- Medical, psychological, cognitive, or other conditions that impair the subject's ability to understand, consent, or comply with protocol procedures.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Bevacizumab plus Erlotinib
Participants will receive Bevacizumab at 7.5 mg/kg intravenously every 3 weeks combined with daily oral Erlotinib at 150 mg. |
Administered at 7.5 mg/kg intravenously every 3 weeks.
Muut nimet:
Administered at 150 mg orally daily.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Progression-Free Survival (PFS)
Aikaikkuna: From the first dose of study treatment until disease progression or death, assessed up to 12 months
|
PFS is calculated from the date of the first administration of the study drug to the date of documented disease progression or death from any cause. |
From the first dose of study treatment until disease progression or death, assessed up to 12 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Objective Response Rate (ORR)
Aikaikkuna: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
|
Proportion of patients who achieve a Complete Response (CR) or Partial Response (PR) evaluated using RECIST version 1.1. |
Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
|
|
Overall Survival (OS)
Aikaikkuna: From the first dose of study treatment until death, assessed up to 1 year of survival follow-up
|
OS is calculated from the date of the first administration of the study drug to the date of death from any cause or the last follow-up date |
From the first dose of study treatment until death, assessed up to 1 year of survival follow-up
|
|
Disease Control Rate (DCR)
Aikaikkuna: Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
|
Proportion of patients who achieve CR, PR, or stable disease (SD) maintained for at least 6 weeks after study drug administration |
Assessed every 6 weeks from baseline until disease progression, up to approximately 12 months
|
|
Duration of Response (DOR)
Aikaikkuna: From initial response until documented disease progression, assessed up to approximately 12 months
|
Calculated from the time initial response (CR or PR) is documented until the date of progressive disease |
From initial response until documented disease progression, assessed up to approximately 12 months
|
|
Time to Response (TTR)
Aikaikkuna: From the first dose of study treatment until the first documented response, assessed up to approximately 12 months
|
Calculated from the first dose of study treatment to the date of initial response (CR or PR) |
From the first dose of study treatment until the first documented response, assessed up to approximately 12 months
|
|
Safety and Tolerability
Aikaikkuna: From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months
|
Evaluated by type, frequency, and severity of adverse events graded according to NCI CTCAE version 5.0 |
From the first dose of study treatment through 28 days after the last dose of study treatment, up to approximately 13 months
|
|
Quality of Life (QoL) EORTC QLQ-C30
Aikaikkuna: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months
|
Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) |
Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months
|
|
Quality of Life (QoL) CR26
Aikaikkuna: Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months
|
Assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (CR26) |
Baseline, every 6 weeks during treatment, and at the end of treatment (EOT), up to approximately 12 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat sivustoittain
- Neoplasmat
- Suoliston sairaudet
- Ruoansulatuskanavan kasvaimet
- Ruoansulatuskanavan kasvaimet
- Ruoansulatuskanavan sairaudet
- Ruoansulatuskanavan sairaudet
- Suoliston kasvaimet
- Peräsuolen sairaudet
- Paksusuolen sairaudet
- Kolorektaaliset kasvaimet
- Aminohapot, peptidit ja proteiinit
- Proteiinit
- Heterosykliset yhdisteet
- Heterosykliset yhdisteet, 2-rengas
- Heterosykliset yhdisteet, sulatettu rengas
- Vasta -aineet, monoklonaalinen, humanisoitu
- Vasta -aineet, monoklonaalinen
- Vasta -aineet
- Immunoglobuliinit
- Immunoproteiinit
- Veriproteiinit
- Seerumin globuliinit
- Globuliinit
- Kinatsoliinit
- Erlotinibihydrokloridi
- Bevasitsumabi
Muut tutkimustunnusnumerot
- COBET
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Yes. De-identified individual participant data underlying the results reported in this article, after de-identification, will be shared beginning 3 months and ending 5 years following article publication to researchers who provide a methodologically sound proposal. Proposals should be directed to the corresponding author. Data getters will be required to sign a data access agreement.
IPD-jaon aikakehys
Beginning 3 months and ending 5 years following article publication.
IPD-jaon käyttöoikeuskriteerit
De-identified individual participant data will be shared with researchers who provide a methodologically sound proposal to achieve the aims of the approved proposal. Proposals should be directed to the corresponding author. Data requesters will be required to sign a data access agreement.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .